R&D Partner Content 9th Microbiome Movement Summit Europe Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential
Partner Content Partner Content Exclusive Interview with Martin Everett, CSO, Antabio, speak... Exclusive Interview with Martin Everett
Partner Content Partner Content SMi’s Pharma Microbiology in Boston 2-day event what to expe... SMi’s Pharmaceutical Microbiology in Boston
Partner Content Partner Content Invite from Lynne Ensor chair for Pharma Microbiology East C... Invite from Lynne Ensor chair for Pharma Microbiology
Partner Content Partner Content Registration Opens for SMi’s 3rd Annual Pharmaceutical Micro... Registration Opens SMi’s Pharma Microbiology Boston
Partner Content Partner Content Top decision makers to present at SMi’s 9th Annual Pharma Mi... Top decision makers to present at Pharma Microbiology
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
